Healthcare Company

The Cambridge Center For Medical & Veterinary Sciences Inc

0%

Funding Goal $1,600,000
Funding Raised So Far $0
Funding Commitments $0
Funding Remaining $1,600,000
Funding Type Common Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Company Overview


The Cambridge Center for Medical & Veterinary Sciences Inc. (CMVS) is focusing its efforts (PHASE ONE of the project) to raise USD 1.6 million for the purpose of establishing kidney transplant program for clinically diagnosed uremic dogs in Greater Toronto Area (GTA) in Ontario, Canada. This will be the first and only such program established in Canada and the U.S.A. In this PHASE ONE, the Company is planning to establish a new 2,500 sq. ft. – 5,000 sq. ft. FACILITY in GTA, where the clinical kidney transplant program for uremic dogs, a lifesaving procedure provided for terminally ill patients, and the staff involved in the transplant program can be incorporated. The FACILITY will provide an environment for generating a revenue (organ transplantation, daily routine in- & out- patient clinical work, auxiliary services, etc.) in the amount of USD 750.000 (very conservative approach) in its first operational year– and the return on investment. Currently, there are no clinical kidney transplant programs for dogs with diagnosed end-stage-kidney disease established in Canada and in the USA.
Approximately 2.25 million of our pets, dogs and cats (1.5% of total population of 150 million), are diagnosed every year with uremia and / or diabetes, of which 40% - 50% are euthanized due to lack of treatment . This licenced FACILITY will set-up a fundamental platform to create a teaching-learning institution as it has been outline in the Phase 2 of this project. GTA is a very unique and only such place (a strip 150 km long and 50 km wide along Lake of Ontario) on the North American continent due to its geography (Grate Lakes – 18 % of the world's fresh lake water), climate (mild winters and hot summers), population (most populous urban region in Canada, with over 5 million people and expected to add another 2.5 to 4 million by 2020), economy (revenue: C$21 billion / year, and rising), and education (numerous of highly educated individuals holding their PhD degrees).

lock icon

Invest in Company

Sign up or log in now to unlock profile details and access financials, company documents, and invest in companies.

Business Summary


Company Age
Employees
Sub-Industry
Prior Year Revenue
Current Year Revenue
Next Year Revenue

Products/Services


Veterinary Transplant Services for Pets With the End-Stage of Kidney Disease

Services in the form of kidney transplant programs, routine in-&-out-patient clinical work, diagnostic work, etc. will be provided to approximately 9,000 clinical patients (dogs) diagnosed with the end stage of kidney disease in Greater Toronto Area (GTA), additionally to approximately 500,000 patients - dogs that are diagnosed every year in the USA with uremia of which 40%-50% are euthanized due to lack of treatment. There are approximately 1,500 hospitals in Ontario providing services to dogs and cats. It is anticipated that each hospital may refer to our FACILITY at least 1 patient / year

Pet Industry

Our FACILITY will be the 1st and only place in Ontario/Canada/USA to provide kidney transplant services to approximately 37,000 pets, dogs/cats (1.5% of total population of 2.5 million living in Greater Toronto Area), additionally to 2.25 million of pets (1.5% of total population of 150 million living in the USA) which are diagnosed every year with uremia / diabetes, of which 40% - 50% are euthanized due to lack of treatment. Pet Industry with spending on veterinary services, pet insurance, grooming, boarding, pet hotels, and pet-sitting is one of the fastest growing industry by 3%-4% per year

Management


Miroslaw P. Ruka
Director
Miroslaw P......

Miroslaw P...... (DVM, PhD) is licensed in the Province of Ontario as a Veterinary Clinical Small Animal Organ Transplant Surgeon, by the College of Veterinarians of Ontario (CVO, license no. 4796, Ontario, Canada), as an only such specialist in Ontario, and in Canada. He has gained his clinical, teaching, applied-clinical research experience with training in soft tissue surgery/microsurgery and organ-transplantation working in an academic environment of Eastern & Western Europe, Middle East, and North America. He is a recipient of two Post-Doctoral Fellowship Awards in the field of organ / tissue transplantation and reconstruction from Holland and Canada. He is also the winner of the best papers presented at the meetings of the European Society for Surgical Research and the Microscopical Society of Canada. He has published more than 80 scientific papers and abstracts in scientific and clinical journals in the field of organ transplantation and related immunology.

Director
Allan S......

Dr. Allan S...... (M.D) is a Professor Emeritus of Surgery and Transplantation at Dalhousie University and the Queen Elisabeth II Health Sciences Center in Halifax. He is graduate in Medicine from Dalhousie University. He did his post-graduate surgical training in the Halifax hospitals with research and training at Harvard University under Professor J.E. Murray and the Cambridge University with Professor Sir R.Y. Calne. He established the kidney transplant program in Halifax in 1969 and has been involved in basic laboratory research in the fields of clinical transplantation and immunology ever since. He has over 250 scientific papers and abstracts published in scientific and clinical journals. He has supervised the introduction of liver / pancreas transplantation to the established kidney program. Dr. is a Fellow of the Royal College of Physicians and Surgeons of Canada and has served as a Member of Council for the College eight years and as an examiner for seven years

0%

Funding Goal $1,600,000
Funding Raised So Far $0
Funding Commitments $0
Funding Remaining $1,600,000
Funding Type Common Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Documents


Contact


The Cambridge Center For Medical & Veterinary Sciences Inc

Guelph, ON N1H 7R4, Canada

Top 10 Tips for Entrepreneurs Seeking Funding

Users who follow these tips increase their fundraising odds substantially.

  • Complete Your Funding Profile
    • Complete your funding profile with all sections filled, including your products and services, a complete management team with headshots, and slideshow with product images.
  • Complete a Business Plan (Optional)
    • Complete a Business Plan in EquityNet and refine your financial projections using the benchmarking alerts in the Business Plan Analysis report.
  • Upload Important Investment Documents
    • Upload and present any other important investment documents such as pitch decks, financial statements, and offering materials.
  • Use EquityNet Crowdcast
    • Use the EquityNet Crowdcast system to automatically email invitations to your contacts in order to build additional exposure for your company.
  • Construct Concise Introductory Messages
    • Construct and send a concise introductory message to investors, including primary reasons why they should want to invest such as KPIs, expected returns, and forecasted revenue.
  • Be Proactive in Messaging Investors
    • Be proactive in messaging many investors and include a simple way for them to connect with you for a web meeting or call, such as a Calendly link.
  • Use the Activity System
    • Use the Activity system to track interested investors, and send prompt follow-up messages to investors who viewed your profile or showed interest.
  • Prepare for Due Diligence
    • Prepare for due diligence questions by interested investors and use your Business Plan and investment documents to satisfy such requests.
  • Keep Your Funding Profile Updated
    • Keep your funding profile updated with new funding raised/committed and message interested investors with any new milestones achieved.
  • Do Not Respond to Unknown Investors
    • Do not respond to or engage any parties outside of EquityNet that are not listed as approved investors (this may happen due to your public profile and LinkedIn connections).